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The convergence of the genomic revolution and biobanking with rapid progress in stem cell research holds
vast potential for personalized medicine and novel therapies. In this Forum, we explore social and ethical
considerations emerging from strategies to realize the promise of these remarkable technologies.In 2005, one of the first genome-wide as-
sociation studies (GWAS) was published,
in which over 116,000 SNPs in 146 indi-
viduals were screened to reveal a comple-
ment factor H polymorphism associated
with age-related macular degeneration
(Klein et al., 2005). Some 2 years later,
successful reprogramming of human
fibroblasts to induced pluripotent stem
cells (iPSCs) was reported (Takahashi
et al., 2007).
Whole-genome analysis technologies,
including microarrays and next-genera-
tion sequencing (NGS), are fueling the dis-
covery of genetic variants associated with
a wide variety of human conditions; both
effect size and allele frequency are critical
dimensions in associating genetic varia-
tion with diseases and other human con-
ditions (Bush and Moore, 2012). Genetic
variants explain only a portion of pheno-
types, with environmental exposures and
epigenetic factors influencing gene
expression and ultimately, human traits.
While stem cell technologies, including
human embryonic stem cells (hESCs),
iPSCs, transdifferentiation, dedifferentia-
tion (Jopling et al., 2011), and adult stem
cells are rapidly accelerating our under-
standing of biology and disease, none of
these have been applied to genetically
characterized samples from a broad pop-
ulation base.
The convergence of next-generation
stem cell and whole-genome analysis
technologies presents an opportunity to
create disease-relevant cell types with
known genetic variants that represent hu-
man populations and could accelerate
personalizedmedicine, advance drug dis-
covery, and broaden our understanding of
disease biology. Such an approach would
discern the biological repercussions of
the alleles, whether common or rare. Theconsequent knowledge could be lever-
aged to find new therapeutics and design
smarter clinical trials with inclusion and
exclusion criteria tailored to expected re-
sponses based on genetic variation (Bellin
et al., 2012). Moreover, biobanks of cells
with known and defined genetic profiles
could facilitate development of cell-based
therapeutics less prone to immune rejec-
tion. Researchers, funding agencies, and
policy makers will need to converge on a
common set of biological, ethical, and so-
cial principles.
Biobanks as a Potential Source
of Next-Generation Stem Cells
To fuel the next wave of regenerative
medicine research and clinical application
development, integrated biobanks are
essential. These integrated biobanks
would support GWAS and also serve as
source material for next-generation stem
cells technologies with known and spe-
cific genetic composition.
Biobanks are repositories of samples
for use in research studies. The biological
material itself is practically uselesswithout
some associated information. Age, sex,
and continent(s) of origin are a few attri-
butes nearly universal to human biobanks.
Biobanks often include medical informa-
tion, particularly if they have been con-
structed to accelerate research in a
particular disease area. Some capture
longitudinal information from individuals
to support population studies, others are
disease-specific, and still others comprise
residual tissues from medical procedures
or diagnoses (Knoppers et al., 2012).
Large-scale biobanks that support
population-based studies such as
GWAS have raised numerous ethical,
legal, and social issues, among them the
potential identification of donors, revela-Cell Stem Cetion of individual genetic predispositions,
and information about biological family
members who may not have provided
any type of informed consent (Cambon-
Thomsen, 2004; Knoppers et al., 2012).
Moreover, there is significant variation
among informed consent for biobanks:
specific to a particular study or broad; ob-
ligations, if any, to return results to do-
nors; and the right of donors to withdrawal
from future studies (Knoppers et al.,
2012). These issues persist and some
are potentiated by the convergence of
large-scale genomic studies and next-
generation stem cell technologies.
However, stem cell experiments differ
conceptually from whole-genome anal-
ysis: they are based on individual samples
rather than populations. Researchers
generally use readily available cellularma-
terial (e.g., rodent cells, cell lines, or
opportunistic clinical specimens) that
may not have been genetically character-
ized. Well-concerted efforts to link stem
cell generation and biobanks of represen-
tative human populations are in their
infancy. One fundamental driver is that
biobanked samples for stem cell genera-
tion have a high bar for preservation: living
cells. Existing tissue biobanks, however,
often lack live, recoverable cellular mate-
rial because the collections predate
next-generation stem cell technologies.
Each of these next-generation technol-
ogies presents challenges with respect to
biobank creation. It is unknown whether
somatic cells commonly used in reprog-
ramming such as dermal fibroblasts retain
cell-of-origin epigenetic memory (Sullivan
et al., 2010) or whether epigenetic
markers will affect models of disease in
derived cell lineages for research or cell-
based therapy. In contrast, dedifferenti-
ated cells may be epigenetically close toll 12, May 2, 2013 ª2013 Elsevier Inc. 513
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Here, only a limited number of steps are
necessary to elicit proliferation without re-
verting all the way to pluripotency. Adult
stem cells are local, organ-specific stem
cells and may be more epigenetically
similar to their differentiated counterparts
within the organ but are extremely rare in
most tissues. Since dedifferentiated and
adult stem cells require the use of local
resident cells, a very limited number of
biobanks exist. Creating new banks for
these methods would require the collec-
tion of cells that are not readily accessible,
such as neurons or pancreatic islet cells,
presenting a significant obstacle for
some conditions. Furthermore, suitable
long-term storage methods for some cell
types do not currently exist.
Future biobanked samples for any stem
cell approach should include accompa-
nying clinical, biological, and sequence
information. Appropriate informed con-
sent will also be necessary and must be
considered in the broader context of the
accentuated ethical, legal, and social is-
sues emerging from the convergence of
whole-genome analysis and next-genera-
tion stem cell technologies.
Ethical, Social, and Policy Issues
Even before the formal launch of the
Human Genome Project (HGP) in 1990,
theUSNational Institutes of Health formed
a joint working group with the Department
of Energy to ‘‘identify and address’’ the
ethical, legal, social, and economic issues
(ELSI) that would arisewith technology ad-
vancements for genomeanalysis (seeWeb
Resources). The first 5 year plan for the
HGP included an ELSI budget allocation,
which continued throughout the 13 year
project. Among these issues are: privacy
and confidentiality, the potential for
discrimination based on genetic informa-
tion, and intellectual property.
The HGP and programs such as Small
Business Innovation Research (SBIR) and
Advanced Technology Program (ATP)
grants accelerated development of
genome analysis technologies in the pri-
vate sector. By the time the HGP was
declared complete in April 2003, a number
of whole-genome analysis studies were
well underway.Theseadvances ingenome
analysis technology quality and declines in
cost havemade privacy protection for bio-
banksamplesuntenable: recently, theabil-
ity to recover surnames from personal514 Cell Stem Cell 12, May 2, 2013 ª2013 Elgenomes and link them to deidentified
public data sets was demonstrated (Gym-
rek et al., 2013). Asdirect-to-consumerge-
netic tests and personal genome initiatives
proliferate, vast amounts of genetic infor-
mation are being generated, stored, and
searched. DNA from shed skin cells or
hair can be collected without permission
or knowledge; massive law enforcement
databases, such as CODIS (see Web
Resources), already exist. Affordable,
easy-to-use DNA sequencing technology
will almost certainly become widely
accessible.
Biobanked tissues and cells contain the
full genomes of the donors; thus, they
include the same ELSI concerns as DNA
samples. Application of next-generation
stem cell technologies to existing bio-
banks will foster applications beyond the
original intent of the biobank. New cells,
cell lines, or tissues with known genetic
profiles are a likely outcome of the
convergence between genome analysis
and stem cell technologies. Such prod-
ucts may outlive the intended research
objectives by several decades, raising
new ELSI concerns. Nonautologous cells
or tissues generated from iPSCs or dedif-
ferentiated cells for regenerativemedicine
applications carry the donor’s genetic in-
formation, subverting the notion of auton-
omy or control over one’s own genetic
information; in theory, the recipient could
decipher the donor’s entire genetic
code, revealing alleles that correlate with
certain behaviors or early-onset, untreat-
able diseases.
Protection against genetic discrimina-
tion remains a vital ELSI concern. Howev-
er, it was not until 2008 that the Genetic
Information Nondiscrimination Act finally
passed the US Congress; its protections
are limited to employment and health in-
surance. In 1997, UNESCO adopted the
Universal Declaration on the Human
Genome and Human Rights (seeWeb Re-
sources), Article 6 of which provided a
more comprehensive statement against
genetic discrimination, including preser-
vation of ‘‘human rights, fundamental
freedoms, and human dignity.’’ Con-
verging advances in genetic analysis and
regenerative medicine magnify the need
for broad genetic information nondiscrim-
ination legislation in UN member nations.
Genetic information should not provide a
basis for discrimination in access to social
services, educational opportunities, orsevier Inc.other aspects of living. Donors to inte-
grated biobanks should be assured that
their participation in no way jeopardizes
future opportunities for themselves or bio-
logical family members.
Informed consent principles for bio-
banked samples are particularly complex
as whole-genome analysis and regenera-
tive medicine technologies converge. An
underlying principle of informed consent
is that individuals choose how and
whether their tissues, cells, DNA, or asso-
ciated data will be used. Some scholars
limit the definition of true informed con-
sent to specific, well-defined research;
others propose that broader consent is a
tractable solution for longitudinal popula-
tion studies. The premise that research
studies be approved by institutional or
ethics review boards is universally held.
The future use of samples presents a
fundamental informed consent challenge
that is accentuated by the preservation
of living tissue that can, in theory,
generate genetically identical tissues, or-
gans, or organisms that may outlive both
the donor and the researcher. Because
science is evolutionary and combinatorial,
the design of future studies cannot be
anticipated at the time samples are
collected. Notification, opt-out, with-
drawal, return-of-results, and incidental
finding provisions provide some potential
solutions (Cambon-Thomsen, 2004;
Knoppers et al., 2012); however, they
impose research transaction costs, which
may appear virtually unlimited in the case
of incidental findings. Implementation of
some informed consent provisions after
death may unintentionally compromise
the privacy of survivors.
Integrated informed consent will be an
essential feature of next-generation bio-
banks. Since the banks will contain live
cells with full genetic information, consent
must encompass future uses of the mate-
rial and the knowledge coming from it. En-
gineered tissues could replace long-term
pharmaceutical treatment for chronic
conditions such as diabetes and heart
disease; would donors of the progenitor
cells be informed of results in recipients,
compromising their privacy? Would
recipients have a right to know the
genetic code of tissues implanted in their
own bodies? Notification and opt-out pro-
visions could become particularly prob-
lematic. Would initial cell donors or their
survivors have any rights to preclude use
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populations because of religious or other
personal beliefs? All future uses cannot
be anticipated or imagined; therefore,
ethics review committees proficient in
both genetic analysis and stem cell
research will be vital, raising the need for
integrated professional development. In
addition to considering the ELSI implica-
tions of genetic information and regenera-
tive medicine, a ‘‘tiered’’ informed con-
sent approach might enable donors to
opt out of future, undefined applications.
Although a meaningful review of gene
and stem cell patents is beyond the con-
fines of this Forum article scope and
space, ownership of biobank samples
and commercial use provisions related
to intellectual property rights merit some
remark (for further reading see Mathews
et al., 2013). Soon, the US Supreme Court
will hear the Association for Molecular
Pathology v. Myriad Genetics case chal-
lenging the validity of the BRCA1 and
BRCA2 gene patents in the US; whether
naturally occurring gene sequences are
patentable varies by country. Similarly,
isolated stem cells are patentable in the
US, but the European Court of Justice
ruled against patents on hESC lines (see
Web Resources).
Patent claims may relate to composi-
tion of matter, e.g., the DNA sequence
or stem cell itself, or to the method or pro-
cess for using matter. Patentable subject
matter usually needs to meet three tests:
novel, nonobvious to one skilled in the
art, and useful. Composition of matter
patents issued on naturally occurring
gene sequences claim novelty because
the sequence is isolated; once a single
gene had been isolated and sequenced,
it seems obvious that one would wish to
isolate and sequence all of them; hence,
the Human Genome Project. The patent-
ability of technologies for genome anal-
ysis, however, is broadly accepted.
Patent filings for pluripotent stem cell
generation and directed differentiation
abound. Because thesemethods are rela-
tively novel, it remains to be seen whether
dominant technology claims will emerge
such as Cohen-Boyer patent for recombi-
nant DNA technology. Many of the earliest
processes using viral vectors are unlikely
to yield cells or tissues that are safe for
regenerative medicine applications; tran-
sient gene suppression for dedifferentia-
tion or reprogramming followed by prolif-eration may have more clinical utility. In
any case, the recent, rapid stem cell
research progress suggests that useful
applications will emerge and require
meaningful intellectual property
protection.
From an intellectual property perspec-
tive, the convergence of whole-genome
analysis and stem cell technologies raises
and accentuates challenging issues: who
‘‘owns’’ an individual’s genetic informa-
tion and the biology it encodes? What
rights, if any, should donors have to
profits generated from organs or tissues
derived from their cells? Who decides on
limitations for use of DNA, cells, tissues,
or organs? The courts thus far have held
that donors do not have ownership rights
in biological materials derived from their
samples; however, the value of geneti-
cally proficient replacement hearts, livers,
and islet cells could impact the calculus of
commercialization over time, especially
as individuals are empowered to under-
stand their own genomes through con-
sumer genetics services.
The ethical and legal issues for regener-
ative medicine diminish substantially
when new stem cell technologies are em-
ployed that enable use of the patient’s
own cells as starting material; the costs
and time to cell and tissue therapies
become predominant factors in the
viability of these approaches. However,
it may not be advisable to treat some
medical conditions with autologous re-
generated cells: they will bear the same
genetics, and possibly, the same epige-
netics. Thus, while autologous cells may
circumvent some ELSI concerns, bio-
banking of allogeneic, genetically profiled
cells may be necessary to realize person-
alized and affordable regenerative medi-
cine. The ELSI considerations are pro-
found and warrant ongoing investment
to fuel thoughtful analysis.
Public investment is essential to realize
the promise of this technology conver-
gence. Integrated biobanks that support
the convergence of GWAS and stem cell
research require infrastructure and stan-
dardization. No perfect technology to
generate stem cells at scale has yet
emerged. Viral reprogramming is best es-
tablished, but raises safety concerns.
Adherent fibroblasts are more suited for
automation, but lymphocytes are more
easily collected. Optimization of methods
and comparative analysis is the first stepCell Stem Cetoward standardization; such efforts are
underway at several institutions and in
industry. To limit variability, stem cell
lines must then be generated using
standard operating procedures (SOPs).
Moving from laboratory-scale stem cell
generation to large cohort analysis raises
new challenges. First, how many clones
need to be generated and characterized
per donor? Investigators using iPSCs
often include three to five clones per indi-
vidual, which would catapult a cohort
of 300 donors to over 1,000 samples.
Second, how many donors represent
a population (a challenge familiar to
GWAS)? Third, should donors be followed
over time to collect material prior to,
during, and after disease to capture
potential epigenetic changes? While
costs are declining, stem cell generation
and differentiation remains laborious
and expensive. A smart selection based
on allele effect size may help to reduce
these numbers. Once integrated bio-
banks are established, standard methods
to differentiate and interrogate cells
of interest also need to be developed.
Funding must be adequate to solve
these technical, biological, and ethical
scenarios over time. Granting agencies
have already crafted RFAs designed
to surface and address some of these
infrastructure and standardization issues
(see Web Resources).
Future Directions
We explore the convergence of two
seemingly unrelated technologies that
now can act in concert to advance our un-
derstanding of human disease and accel-
erate development of potential therapies.
To realize this potential, we need to
reimagine biobanks as core infrastructure
to generate stem cells on a population
scale. Future ‘‘centers of excellence’’ for
biobanking should employ cell biologists,
bioinformaticians, clinicians, ethics advi-
sors, and policy makers. At these centers,
standardized cell collection and cell pro-
duction should be driven by SOPs; perti-
nent biomedical and bioinformatics data
should be available in an open, search-
able format with the option and require-
ment for resubmission of phenotypic and
cellular data.
Both the biobank infrastructure and
thoughtful analysis of novel as well as
accentuated ethical, legal, and social is-
sues emerging from the convergence ofll 12, May 2, 2013 ª2013 Elsevier Inc. 515
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research require significant investment.
Some initial efforts are underway through
CIRM and NIH (see Web Resources);
recently, the Japanese government
announced a $1 billion investment in
regenerative medicine ventures based
on iPSCs (see Web Resources). While
difficult to quantify, platform investments
in biological sciences seem to pay off:
the US government estimates an eco-
nomic impact of $140 for each of the
$3.8 billion invested in the HGP from
1990–2003 (see Web Resources). Ima-
gine the collective improvement in quality
of life and economic return with invest-
ment that accelerates the convergence
of genome-wide analysis and stem cell
research.WEB RESOURCES
The URLs for data presented herein are as follows:
Embryonic Stem Cells. http://stemcells.nih.
gov/Pages/Default.aspx516 Cell Stem Cell 12, May 2, 2013 ª2013 ElNobel Prize for cellular reprogramming http://
www.nobelprize.org/nobel_prizes/medicine/
laureates/2012
Stem cells clinical trials. http://clinicaltrials.gov/
ct2/show/NCT01217008?term=geron&recr=
Open&rank=5
CODIS. http://www.fbi.gov/about-us/lab/
biometric-analysis/codis
Human Genome Project ELSI issues. http://
www.ornl.gov/sci/techresources/Human_
Genome/publicat/hgn/v2n1/05elsi.shtml
European hESCs. http://www.nature.com/
news/2011/111024/full/478441a.html http://
www.ornl.gov/sci/techresources/Human_
Genome/publicat/hgn/v2n1/05elsi.shtml
RFAs to standardize stem cell production.
http://www.cirm.ca.gov/about-cirm/newsroom/
press-releases/03192013/stem-cell-agency-
banks-32-million-new-approach-advance
UNESCODeclaration. http://portal.unesco.org/
en/ev.php-URL_ID=13177&URL_DO=DO_
TOPIC&URL_SECTION=201.html
Japan’s investment in iPSCs. http://www.
economist.com/news/business/21572235-
best-market-world-right-now-regenerative-
medicine
Return on the Human Genome Project. http://
www.genome.gov/27544383sevier Inc.REFERENCES
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